Motesanib trial in NSCLC patients is suspended

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Amgen and Millennium, a subsidiary of Takeda Pharmaceutical Company Limited, have suspended enrollment in the phase III Motesanib NSCLC Efficacy and Tolerability Study.

Amgen and Millennium, a subsidiary of Takeda Pharmaceutical Company Limited, have suspended enrollment in the phase III Motesanib NSCLC Efficacy and Tolerability Study.

During a planned safety data review, an independent data monitoring committee evaluated data from 600 patients taking treatment for advanced non-small-cell lung cancer (NSCLC). The committee observed higher early mortality rates in the motesanib group compared to the placebo group and recommended stopping enrollment.

The trial was designed to evaluate motesanib (AMG 706) in combination with paclitaxel and carboplatin. The monitoring committee suggested that patients stop taking motesanib if they had squamous NSCLC, due to a higher incidence of hemoptysis.

However, the safety board did not recommend discontinuing motesanib therapy for patients with nonsquamous NSCLC. The DMC will review updated data after three months.

In other news, Amgen announced results of a biomarker analysis that bolstered the efficacy of panitumumab monotherapy (Vectibix) in colon cancer patients with wild-type KRAS tumors who failed all other chemtherapeutic regimens. In patients with non-mutated KRAS tumors, Vectibix signifi cantly increased progression- free survival and quality of life.

The data from the phase III, randomized, controlled trials will be presented at the ASCO 2009 Gastrointestinal Cancers Symposium in San Francisco.

Articles in this issue
Radiology resident compiles staging database
Study links the risk of ALCL to silicone breast implants
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma
Clara Bloomfield: Buck conventional wisdom always
New breast cancer program reduces time to treatment
PET/CT for prostate ca influences staging, treatment strategy
Racially-based disparities in ca on the rise, not due to smoking
ProStrakan offers patch to prevent nausea and vomiting
Online tool encourages families to bone up on genetics
Bevacizumab plus copper radiotracer shines as imaging probe
Coverting unresectable to resectable: Data still limited
AACR commits to Love/Avon Army of Women
Voters pass end-of-life measure in Washington state
Brachytherapy improves treatment in augmented women
Marathon effort to support cancer care
Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content
According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.

The Paradigm of AML Care: What’s New and What’s Changing

Tim Cortese
November 30th 2025
Article

According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC

HRQOL Finds Similar Responses Between Surgery/Treatment Options in NMIBC

Ariana Pelosci
November 29th 2025
Article

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.